190 related articles for article (PubMed ID: 22788573)
1. Pneumatosis intestinalis and hepatic portal venous gas in a patient receiving sorafenib.
Kashima T; Ohno Y; Tachibana M
Int J Urol; 2012 Nov; 19(11):1041-2. PubMed ID: 22788573
[No Abstract] [Full Text] [Related]
2. Abdominal Distension in a Patient With Hepatocellular Carcinoma. Benign Pneumatosis Intestinalis and Pneumoperitoneum Associated With Sorafenib Therapy.
Huang YH; Siao FY; Yen HH
Gastroenterology; 2015 Aug; 149(2):e12-3. PubMed ID: 26123559
[No Abstract] [Full Text] [Related]
3. Sorafenib induced eruptive melanocytic lesions.
Uhlenhake EE; Watson AC; Aronson P
Dermatol Online J; 2013 May; 19(5):18184. PubMed ID: 24011281
[TBL] [Abstract][Full Text] [Related]
4. A Case of Pancreatic Side Effects Resulting from Sorafenib and Axitinib Treatment of Stage IV Renal Cell Carcinoma.
Kitamura Y; Yoshii H; Nishimoto K; Shinchi Y; Tokonabe S; Takao M; Daido Y
Keio J Med; 2015; 64(4):62-4. PubMed ID: 26727578
[TBL] [Abstract][Full Text] [Related]
5. Sorafenib-induced tuberculosis reactivation.
Teo M; O'Connor TM; O'Reilly SP; Power DG
Onkologie; 2012; 35(9):514-6. PubMed ID: 23007150
[TBL] [Abstract][Full Text] [Related]
6. Spontaneous regression of metastatic papillary renal cell cancer after cessation of treatment with sorafenib.
Grenader T; Rosenbaum E; Zilber S; Bogot N; Shavit L
Clin Genitourin Cancer; 2013 Jun; 11(2):201-3. PubMed ID: 23266054
[No Abstract] [Full Text] [Related]
7. Delayed onset perforating folliculitis associated with sorafenib.
Batalla A; Menéndez L; Blay P; Curto JR
Australas J Dermatol; 2014 Aug; 55(3):233-5. PubMed ID: 25117168
[No Abstract] [Full Text] [Related]
8. Stevens-Johnson syndrome induced by sorafenib for metastatic renal cell carcinoma.
Ikeda M; Fujita T; Amoh Y; Mii S; Matsumoto K; Iwamura M
Urol Int; 2013; 91(4):482-3. PubMed ID: 23969404
[TBL] [Abstract][Full Text] [Related]
9. [Drug now immediately available in Germany].
Aktuelle Urol; 2006 Sep; 37(5 Suppl):18-9. PubMed ID: 23646396
[No Abstract] [Full Text] [Related]
10. A case of reversible cardiomyopathy associated with sorafenib in advanced hepatocellular carcinoma.
Park H; Han SH; Kang H; Park K
Int J Cardiol; 2012 Sep; 160(1):e10-1. PubMed ID: 22289299
[No Abstract] [Full Text] [Related]
11. Hyperthyroidism and thyroid autoimmunity induced by sorafenib in metastatic renal cell cancer.
Konca Degertekin C; Coşkun U; Baloş Törüner F; Aktürk M; Demirci U
Endocrine; 2012 Dec; 42(3):756-7. PubMed ID: 22562706
[No Abstract] [Full Text] [Related]
12. [Side effects of sorafenib and countermeasures].
Nakayama M; Arai Y; Nishimura K
Hinyokika Kiyo; 2012 Nov; 58(11):635-7. PubMed ID: 23254792
[TBL] [Abstract][Full Text] [Related]
13. Multiple squamous cell carcinomas following treatment with sorafenib for renal cell carcinoma.
El Tal AK; Remichofsky CJ; Mehregan DA; Ganger LK
Int J Dermatol; 2013 Dec; 52(12):1538-41. PubMed ID: 23676092
[No Abstract] [Full Text] [Related]
14. Management of sorafenib-related adverse events: a clinician's perspective.
Brose MS; Frenette CT; Keefe SM; Stein SM
Semin Oncol; 2014 Feb; 41 Suppl 2():S1-S16. PubMed ID: 24576654
[TBL] [Abstract][Full Text] [Related]
15. Sorafenib-induced hand-foot syndrome in a patient of renal cell carcinoma.
Sil A; Das NK
Indian J Pharmacol; 2014; 46(3):334-6. PubMed ID: 24987183
[TBL] [Abstract][Full Text] [Related]
16. Sorafenib in renal cell carcinoma.
Davoudi ET; bin-Noordin MI; Javar HA; Kadivar A; Sabeti B
Pak J Pharm Sci; 2014 Jan; 27(1):203-8. PubMed ID: 24374450
[TBL] [Abstract][Full Text] [Related]
17. Management of common adverse events in patients treated with sorafenib: nurse and pharmacist perspective.
Walko CM; Grande C
Semin Oncol; 2014 Feb; 41 Suppl 2():S17-28. PubMed ID: 24576655
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of First-Line Sorafenib Treatment for Metastatic Renal Cell Carcinoma in Kidney Transplant Patients: A Single-Center Experience With Four Cases.
Ishihara H; Kondo T; Tanabe K
Ther Apher Dial; 2017 Aug; 21(4):414-416. PubMed ID: 28593648
[No Abstract] [Full Text] [Related]
19. Sorafenib (Nexavar) for thyroid cancer.
Med Lett Drugs Ther; 2014 May; 56(1443):43-4. PubMed ID: 24869715
[No Abstract] [Full Text] [Related]
20. Cardiovascular comorbidities for prediction of progression-free survival in patients with metastatic renal cell carcinoma treated with sorafenib.
Szmit S; Zaborowska M; Waśko-Grabowska A; Żołnierek J; Nurzyński P; Filipiak KJ; Opolski G; Szczylik C
Kidney Blood Press Res; 2012; 35(6):468-76. PubMed ID: 22688785
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
